logo

For the Inventor, By the Inventor

Beijing, China

Dajun Deng

This inventor holds 4 USPTO granted patents and 3 EPO patents. Top assignee: Beijing Institute for Cancer Research. Active years: 2016-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dajun Deng. Retrieved from https://idiyas.com/inventor/dajun-deng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4

% Patents Active = 50.0

 

Average Co-Inventor Count = 3.7

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:

goldMedal4 out of 10 
 
Beijing Institute for Cancer Research
 patents

Years Active: 2016-2024

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents
1. 12018335 - Method for quantitatively detecting deletion of human CDKN2A gene copy, primers and use thereof (2024-06-25),
2. 10214778 - Methods and nucleotide fragments of predicting occurrence, metastasis of cancers and patients' postoperative survival in vitro (2019-02-26),
3. 9637797 - Methods and nucleotide fragments of predicting occurrence, metastasis of cancers and patients' postoperative survival in vitro (2017-05-02),
4. 9416423 - Primer group for detecting CPG island methylation of P16 gene using methylation-specific fluorescence technique (2016-08-16),

Title: Dajun Deng: Innovator in Cancer Research

Introduction

Dajun Deng is a prominent inventor based in Beijing, China. He has made significant contributions to the field of cancer research, particularly in the development of methods for detecting genetic deletions and predicting cancer outcomes. With a total of 4 patents, his work has the potential to impact cancer diagnostics and treatment.

Latest Patents

Dajun Deng's latest patents include a method for quantitatively detecting the deletion of the human CDKN2A gene copy. This invention provides a set of primer pairs and probes with specific oligonucleotide sequences, enabling the detection of a common deleted region of the CDKN2A gene. The method offers higher sensitivity compared to conventional detection methods, making it a valuable tool for cancer diagnostics. Another notable patent involves methods and nucleotide fragments for predicting the occurrence and metastasis of cancers, as well as patients' postoperative survival. This invention utilizes in vitro measurements of methylation or demethylation of GFRa1 CpG islands to estimate tumorigenesis risk and life expectancy.

Career Highlights

Dajun Deng is affiliated with the Beijing Institute for Cancer Research, where he conducts his innovative research. His work focuses on developing advanced techniques for cancer detection and prognosis, contributing to the ongoing fight against cancer.

Collaborations

Dajun has collaborated with notable colleagues, including Jing Zhou and Zhaojun Liu, to further enhance the impact of his research in the field of cancer.

Conclusion

Dajun Deng's contributions to cancer research through his innovative patents demonstrate his commitment to improving cancer diagnostics and patient outcomes. His work continues to pave the way for advancements in the understanding and treatment of cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…